Want to see ALXO full AI Analyst Report?
Total Valuation
ALX Oncology Holdings has a market cap or net worth of $277.94M. The enterprise value is $153.58.
Market Cap$277.94M
Enterprise Value$153.58
Share Statistics
ALX Oncology Holdings has 138,277,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding138,277,000
Owned by Insiders9.79%
Owned by Institutions0.16%
Financial Efficiency
ALX Oncology Holdings’s return on equity (ROE) is -3.91 and return on invested capital (ROIC) is -261.95%.
Return on Equity (ROE)-3.91
Return on Assets (ROA)-1.72
Return on Invested Capital (ROIC)-261.95%
Return on Capital Employed (ROCE)-3.02
Revenue Per Employee0.00
Profits Per Employee-2.37M
Employee Count43
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ALX Oncology Holdings is ―. ALX Oncology Holdings’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.33
Price to Fair Value2.33
Price to FCF-0.72
Price to Operating Cash Flow-3.72
PEG Ratio0.02
Income Statement
In the last 12 months, ALX Oncology Holdings had revenue of 0.00 and earned -101.69M in profits. Earnings per share was -1.90.
Revenue0.00
Gross Profit0.00
Operating Income-104.02M
Pretax Income-101.69M
Net Income-101.69M
EBITDA-99.39M
Earnings Per Share (EPS)-1.90
Cash Flow
In the last 12 months, operating cash flow was -70.78M and capital expenditures -172.00K, giving a free cash flow of -70.95M billion.
Operating Cash Flow-70.78M
Free Cash Flow-70.95M
Free Cash Flow per Share-0.51
Dividends & Yields
ALX Oncology Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change193.94%
50-Day Moving Average1.89
200-Day Moving Average1.77
Relative Strength Index (RSI)51.19
Average Volume (3m)1.65M
Important Dates
ALX Oncology Holdings upcoming earnings date is Nov 5, 2026, After Close (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
ALX Oncology Holdings as a current ratio of 2.07, with Debt / Equity ratio of 7.13%
Current Ratio2.07
Quick Ratio2.07
Debt to Market Cap0.09
Net Debt to EBITDA0.11
Interest Coverage Ratio-64.93
Taxes
In the past 12 months, ALX Oncology Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ALX Oncology Holdings EV to EBITDA ratio is -0.50, with an EV/FCF ratio of -0.59.
EV to Sales0.00
EV to EBITDA-0.50
EV to Free Cash Flow-0.59
EV to Operating Cash Flow-0.59
Balance Sheet
ALX Oncology Holdings has $138.23M in cash and marketable securities with $9.71M in debt, giving a net cash position of $128.52M billion.
Cash & Marketable Securities$138.23M
Total Debt$9.71M
Net Cash$128.52M
Net Cash Per Share$0.93
Tangible Book Value Per Share$0.48
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ALX Oncology Holdings is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.00
Price Target Upside97.04% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast48.20%